Abstract
CD6, one of the first antigens to be identified on T cells, is a membrane glycoprotein that physically associates with the antigen receptor complex. Because of this, its main function seems to involve the modulation of TCR-mediated signaling pathways. However, growing evidence indicates that this ancient and conserved scavenger-like receptor may also play a role as pattern recognition receptor (PRR), similar to other members of the scavenger receptor cysteine rich superfamily (SRCR-SF). Here, we discuss the functional interactions of CD6 with microbe- and damage-associated signals and the potential use of soluble forms of CD6 in the therapeutic treatment of bacterial infections, in particular multi-drug resistant bacterial strains. Importantly, microbe recognition by CD6 may also have functional consequences on T cell activation and differentiation, which remain to be explored.
Keywords: Bacteria, CD5, CD6, lipopolysaccharide, lipoteichoic acid, pathogen-associated molecular patterns (PAMPs), pattern- recognition receptor (PRR), peptidoglycan, scavenger receptor cysteine-rich (SRCR).
Graphical Abstract
Current Drug Targets
Title:Pattern Recognition by CD6: A Scavenger-Like Lymphocyte Receptor
Volume: 17 Issue: 6
Author(s): Adelaida Sarukhan, Mario Martinez-Florensa, Cristina Escoda-Ferran, Esther Carrasco, Esther Carreras and Francisco Lozano
Affiliation:
Keywords: Bacteria, CD5, CD6, lipopolysaccharide, lipoteichoic acid, pathogen-associated molecular patterns (PAMPs), pattern- recognition receptor (PRR), peptidoglycan, scavenger receptor cysteine-rich (SRCR).
Abstract: CD6, one of the first antigens to be identified on T cells, is a membrane glycoprotein that physically associates with the antigen receptor complex. Because of this, its main function seems to involve the modulation of TCR-mediated signaling pathways. However, growing evidence indicates that this ancient and conserved scavenger-like receptor may also play a role as pattern recognition receptor (PRR), similar to other members of the scavenger receptor cysteine rich superfamily (SRCR-SF). Here, we discuss the functional interactions of CD6 with microbe- and damage-associated signals and the potential use of soluble forms of CD6 in the therapeutic treatment of bacterial infections, in particular multi-drug resistant bacterial strains. Importantly, microbe recognition by CD6 may also have functional consequences on T cell activation and differentiation, which remain to be explored.
Export Options
About this article
Cite this article as:
Sarukhan Adelaida, Martinez-Florensa Mario, Escoda-Ferran Cristina, Carrasco Esther, Carreras Esther and Lozano Francisco, Pattern Recognition by CD6: A Scavenger-Like Lymphocyte Receptor, Current Drug Targets 2016; 17 (6) . https://dx.doi.org/10.2174/1389450116666150316224308
DOI https://dx.doi.org/10.2174/1389450116666150316224308 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metabolic Changes in Autoimmune Diseases
Current Drug Discovery Technologies A Possible Role for Interleukin 37 in the Pathogenesis of Behcet's Disease
Current Molecular Medicine Development of Nucleic Acid Drugs for Neurological Disorders
Current Topics in Medicinal Chemistry CC Chemokine Receptor Small Molecule Antagonists in the Treatment of Rheumatoid Arthritis and Other Diseases: A Current View
Current Topics in Medicinal Chemistry Curcumin Conjugates and Metallocomplexes as Lead Compounds for Development of Anticancer Agents - A Short Review
Current Bioactive Compounds Inflammation and Immunology of the Vitreoretinal Compartment
Inflammation & Allergy - Drug Targets (Discontinued) Emerging Evidence for the Role of Neurotransmitters in the Modulation of T Cell Responses to Cognate Ligands
Central Nervous System Agents in Medicinal Chemistry In Vivo Imaging of the Diseased Nervous System: An Update
Current Pharmaceutical Design Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Schizophrenia and Depression: Findings in Humans, and Animal Models
Current Neuropharmacology Antiviral Treatment of Chikungunya Virus Infection
Infectious Disorders - Drug Targets Endothelial Chemokines in Autoimmune Disease
Current Pharmaceutical Design High Dose Immunoglobulin (IVIG) May Reduce the Incidence of Langerhans Cell Histiocytosis (LCH)-Associated Central Nervous System Involvement
CNS & Neurological Disorders - Drug Targets Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry NLRP3 Is Involved in Ischemia/Reperfusion Injury
CNS & Neurological Disorders - Drug Targets Nitric Oxide: Target for Therapeutic Strategies in Alzheimers Disease
Current Pharmaceutical Design Immune Aging and Autoimmune Diseases in Children
Current Immunology Reviews (Discontinued) Subcutaneous Immunoglobulins: A Promising Alternative for Immunomodulation?
Current Pharmaceutical Design The Biology of Persistent Infection: Inflammation and Demyelination Following Murine Coronavirus Infection of the Central Nervous System
Current Immunology Reviews (Discontinued) Subject Index
Current Drug Targets - Inflammation & Allergy ADAM8/MS2/CD156, an Emerging Drug Target in the Treatment of Inflammatory and Invasive Pathologies
Current Pharmaceutical Design